Evidence map›Paper›PMID 33633400›Full record

ArticleNature structural & molecular biology2021

Target-induced clustering activates Trim-Away of pathogens and proteins.

Jingwei Zeng, Ana Filipa Santos, Aamir S Mukadam, Mariana Osswald, David A Jacques, Claire F Dickson, Stephen H McLaughlin, Christopher M Johnson, Leo Kiss, Jakub Luptak and 6 more

Open access · greenAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Targeted Degradation of Mouse Embryo Proteins Using Trim-Away.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Optogenetic engineering for precision cancer immunotherapy.Trends in pharmacological sciences · 2025
    Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Jingwei ZengMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.
Ana Filipa Santosi3S-Instituto de Investigação e Inovação em Saúde and IBMC Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.ORCID http://orcid.org/0000-0002-1315-8881
Aamir S MukadamDepartment of Clinical Neurosciences, UK Dementia Research Institute, University of Cambridge, Cambridge, UK.
Mariana Osswaldi3S-Instituto de Investigação e Inovação em Saúde and IBMC Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.
David A JacquesEMBL Australia Node, Single Molecule Science, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-6426-4510
Claire F DicksonEMBL Australia Node, Single Molecule Science, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia.
Stephen H McLaughlinMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.ORCID http://orcid.org/0000-0001-9135-6253
Christopher M JohnsonMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.ORCID http://orcid.org/0000-0002-5900-3068
Leo KissMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.ORCID http://orcid.org/0000-0001-8735-1118
Jakub LuptakMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.ORCID http://orcid.org/0000-0002-9527-8755
Nadine RennerMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.
Marina VaysburdMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.
William A McEwanDepartment of Clinical Neurosciences, UK Dementia Research Institute, University of Cambridge, Cambridge, UK. wm305@cam.ac.uk.ORCID http://orcid.org/0000-0002-4408-0407
Eurico Morais-de-Sái3S-Instituto de Investigação e Inovação em Saúde and IBMC Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal. eurico.sa@ibmc.up.pt.ORCID http://orcid.org/0000-0003-3525-8231
Dean CliftMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK. dclift@mrc-lmb.cam.ac.uk.ORCID http://orcid.org/0000-0001-8141-7817
Leo C JamesMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK. lcj@mrc-lmb.cam.ac.uk.ORCID http://orcid.org/0000-0003-2131-0334
MRC Laboratory of Molecular Biology · GBi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTUniversity of Cambridge · GBUNSW Sydney · AU

Funding

Medical Research Council MC_U105181010Medical Research Council MC_U105184326Medical Research Council U105181010Wellcome Trust 200594Wellcome Trust 200594/Z/16/ZWellcome Trust 206248Wellcome Trust 206248/Z/17/Z
6 · The paper itself

Abstract

Trim-Away is a recently developed technology that exploits off-the-shelf antibodies and the RING E3 ligase and cytosolic antibody receptor TRIM21 to carry out rapid protein depletion. How TRIM21 is catalytically activated upon target engagement, either during its normal immune function or when repurposed for targeted protein degradation, is unknown. Here we show that a mechanism of target-induced clustering triggers intermolecular dimerization of the RING domain to switch on the ubiquitination activity of TRIM21 and induce virus neutralization or drive Trim-Away. We harness this mechanism for selective degradation of disease-causing huntingtin protein containing long polyglutamine tracts and expand the Trim-Away toolbox with highly active TRIM21-nanobody chimeras that can also be controlled optogenetically. This work provides a mechanism for cellular activation of TRIM RING ligases and has implications for targeted protein degradation technologies.

Indexed as

ProteolysisUbiquitinationAnimalsBiocatalysisCell LineDrosophila melanogasterHumansHuntingtin ProteinMiceModels, MolecularOptogeneticsPeptidesProtein BindingProtein MultimerizationRibonucleoproteinsSS-A AntigenHTT protein, humanHuntingtin ProteinPeptidespolyglutamineRibonucleoproteinsSS-A AntigenUbiquitin-Protein Ligases

Identifiers

PMID33633400
PMCPMC7611929
OpenAlexW3130816211

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.